The latest iteration of the commercial insurance tactics aimed at mitigating the cost of expensive specialty drugs involves tapping patient assistance programs to the extent that manufacturers can bear the entire cost of their drugs.
Known as “alternative funding,” such programs represent the most controversial of the moves and counter-moves employed by payers in recent...







